EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Conditioning therapy with N‐acetyl‐L ‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation

Yaqiong Tang, Ziyan Zhang, Silu Liu, Yifang Yao, Tingting Pan, Jiaqian Qi, Huizhu Kang, Yuejun Liu, Chengsen Cai, Meng Zhou, Xuefeng He, Xiaohui Hu und 3 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26903 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Yaqiong Tang und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Hematopoietic Stem Cell Transplantation, Neoplasms, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conditioning therapy is an essential procedure prior to hematopoietic stem cell transplant (HSCT), imposing a great impact on the outcomes of recipients. We performed a prospective randomized controlled trial to assess the outcome of HSCT recipients with myeloid malignancies after receiving the conditioning therapy consisting of modified BUCY (mBUCY), N‐acetyl‐L‐cysteine (NAC), and decitabine. Enrolled patients were randomly allocated to either Arm A (decitabine, day −12 to −10; NAC, day −9 to +30; mBUCY, day −9 to −2), or Arm B (mBUCY regimen followed by stem cells infusion). Seventy‐six patients in Arm A and 78 patients in Arm B were finally evaluated. The results showed platelet recovery accelerate in Arm A, with more patients achieving a platelet count of ≥50 × 10 9 /L than Arm B at day +30 and +60 ( p = .004 and .043, respectively). The cumulative incidence of relapse is 11.8% (95% CI 0.06–0.22) in Arm A, and 24.4% (95% CI 0.16–0.35) in Arm B ( p = .048). The estimated 3‐year overall survival rate was 86.4% (±4.4%) and 79.9% (±4.7%) in 2 arms, respectively ( p = .155). EFS at 3 years was 79.2% (±4.9%) in Arm A and 60.0% (±5.9%) in Arm B ( p = .007). Intracellular reactive oxygen species (ROS) level was found to be reversely correlated with platelet recovery, and fewer patients in Arm A displayed excessive ROS within hematopoietic progenitor cells compared to Arm B. In conclusion, the addition of decitabine and NAC to mBUCY is a feasible and promising conditioning therapy for myeloid malignancies patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersHematopoietic Stem Cell TransplantationNeoplasmsLeukemia, Myeloid, AcuteGraft vs Host DiseaseHumansDecitabineAcetylcysteineBusulfanProspective StudiesReactive Oxygen SpeciesBehavior TherapyTransplantation Conditioning

Substanzen

DecitabineAcetylcysteineBusulfanReactive Oxygen Species

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
  • Suzhou Hongci Hematology Hospital, Suzhou, China.
  • State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.

ORCID-Profile: Xiao Ma, Yue Han

Förderung

  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions

Zitieren

APA

Tang, Y., Zhang, Z., Liu, S., Yao, Y., Pan, T., Qi, J., Kang, H., Liu, Y., Cai, C., Zhou, M., He, X., Hu, X., Ma, X., Wu, D., & Han, Y. (2023). Conditioning therapy with N‐acetyl‐L ‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.26903

Vancouver

Tang Y, Zhang Z, Liu S, Yao Y, Pan T, Qi J, et al. Conditioning therapy with N‐acetyl‐L ‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. American Journal of Hematology. 2023. doi:10.1002/ajh.26903

BibTeX
@article{Tang2023,
  author = {Tang, Yaqiong and Zhang, Ziyan and Liu, Silu and Yao, Yifang and Pan, Tingting and Qi, Jiaqian and Kang, Huizhu and Liu, Yuejun and Cai, Chengsen and Zhou, Meng and He, Xuefeng and Hu, Xiaohui and Ma, Xiao and Wu, Depei and Han, Yue},
  title = {Conditioning therapy with N‐acetyl‐L ‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26903}
}
Kostenlos starten →